Kyowa Kirin gives Parkinson's drug another shot under SPA
This article was originally published in Scrip
Executive Summary
Despite a long and troubled development history, Kyowa Hakko Kirin continues to believe in the therapeutic value of its Parkinson's disease drug istradefylline, and has just started a new international Phase III program with the first-in-class oral adenosine A2A receptor antagonist with an eye on trying again for a US approval.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.